Study of Compound Edaravone Injection for Treatment of Acute Ischemic Stroke
A phase 2 trial registered on ClinicalTrials.gov. The registry status is suspended. It plans to enroll 240 participants.
Also called NCT04984577
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 240 participants
- Sponsor
- Nanjing Yoko Biomedical Co., Ltd.
- Registry
-
NCT04984577
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Suspended
Technical summary
Registry record NCT04984577. Randomized; quadruple masking; primary purpose treatment. Start 2021-11-15 (actual); primary completion 2026-12-31 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Study of Compound Edaravone Injection for Treatment of Acute Ischemic Stroke
- Condition
- Acute Ischemic Stroke
- Intervention (Drug)
- Compound Edaravone Injection-Low dose
- Intervention (Drug)
- Compound Edaravone Injection-High dose
- Intervention (Drug)
- Edaravone Injection
- Intervention (Drug)
- Placebo injection
- Lead sponsor
- Nanjing Yoko Biomedical Co., Ltd.
Record details
- Record id
cardio:ct-nct04984577- Content hash
a318af92b7cf4d50436295657216b3d187abf8e17245b3ddce88f438f875a07d